The elvitegravir and cobicistat approvals are not a “big deal,” says Dr. Paul Sax in
HIV and ID Observations.
In the latest HIV and ID Observations blog post, Dr. Paul Sax explains why the recent FDA approvals of cobicistat and elvitegravir will likely have little short-term effect on clinical practice. And he reveals how Canada outshines us with a more-significant approval.